Cover Image
市場調查報告書

球黴菌症治療藥:開發中產品分析

Coccidioidomycosis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 474980
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
球黴菌症治療藥:開發中產品分析 Coccidioidomycosis - Pipeline Review, H2 2017
出版日期: 2017年08月08日 內容資訊: 英文 43 Pages
簡介

本報告提供球黴菌症治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中治療藥,治療藥評估,暫停中·中止的計劃等相關資訊。

簡介

  • 調查範圍

球黴菌症 - 概要

球黴菌症 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

球黴菌症 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

球黴菌症的開發治療藥的企業

球黴菌症 - 藥物簡介

球黴菌症 - 暫停中的計劃

球黴菌症 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9603IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coccidioidomycosis - Pipeline Review, H2 2017, provides an overview of the Coccidioidomycosis (Infectious Disease) pipeline landscape.

Coccidioidomycosis, also called Valley fever, is an infection caused by the fungus Coccidioides. Symptoms include fever, cough, chest pain, chills, headache, fatigue and joint aches. Risk factors include weakened immune system, age, pregnancy, race and environmental exposure. Treatment includes antifungal medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coccidioidomycosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Coccidioidomycosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coccidioidomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Coccidioidomycosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Coccidioidomycosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Coccidioidomycosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Coccidioidomycosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Coccidioidomycosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Coccidioidomycosis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Coccidioidomycosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Coccidioidomycosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Coccidioidomycosis - Overview
    • Coccidioidomycosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Coccidioidomycosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Coccidioidomycosis - Companies Involved in Therapeutics Development
    • Amplyx Pharmaceuticals Inc
    • Valley Fever Solutions Inc
    • Viamet Pharmaceuticals Inc
    • Coccidioidomycosis - Drug Profiles
  • Amphotericin B sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coccidioidomycosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nikkomycin Z - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-1161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-1598 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Coccidioidomycosis - Dormant Projects
  • Coccidioidomycosis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 13, 2017: FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever
      • May 17, 2017: Viamet To Present Data on VT-1598 at The American Society for Microbiology's ASM Microbe 2017 Conference
      • Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
      • Sep 15, 2016: FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever
      • Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
      • May 25, 2016: Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis
      • May 20, 2015: Viamet Announces NIH Grant for Compounds Directed at Valley Fever
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Coccidioidomycosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Coccidioidomycosis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2017
  • Coccidioidomycosis - Pipeline by Valley Fever Solutions Inc, H2 2017
  • Coccidioidomycosis - Pipeline by Viamet Pharmaceuticals Inc, H2 2017
  • Coccidioidomycosis - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Coccidioidomycosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top